Advanced Malignancy, Advanced Solid Tumors, Cancer, Solid Tumors, Tumors
Conditions
Keywords
Amgen, Phase 1, First in Human, Advanced Solid Tumors, Clinical Trial, Aurora kinase inhibitor, Open-label, Oncology
Brief summary
This first-in-human study of AMG 900 will be conducted in two parts: dose escalation and dose expansion. The dose escalation part of the study is aimed at evaluating the safety, tolerability and PK of oral AMG 900 in subjects with advanced solid tumors. Up to 50 subjects may be enrolled in dose escalation. The dose expansion part of the study will consist of 42 subjects in three taxane-resistant tumor types. The dose of AMG 900 will be dependent upon data from the dose escalation part of the study
Detailed description
that G-CSF must be started at day 5, 1 day after the last day of AMG 900 and be continued until neutrophiles are \> 1000 or until day 12, meaning 2 days before the reinduction.
Interventions
AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
DRUGArm 1- Dose Expansion
AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
Sponsors
Amgen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men or women ≥ 18 years old * Part 1 Dose Escalation only: advanced solid tumor refractory to standard treatment for which no standard therapy is available or the subject refuses standard therapy * Part 1 Dose Escalation only: Measurable or evaluable disease per RECIST guidelines * Part 2 Dose Expansion only: Taxane-resistant tumor (defined as refractory to or progression within 6 months of discontinuing paclitaxel or docetaxel) of prespecified histology * Part 2 Dose Expansion only: Measurable disease per RECIST guidelines * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2 * Life expectancy of \> 3 months, in the opinion of the investigator * Willing to provide existing and/or future paraffin-embedded tumor samples * Part 1 Dose Escalation: must have tumor tissue that is accessible for biopsy by fine needle aspiration (FNA) and must consent to undergo biopsies of their tumor (subjects in non-accelerated phase only) * Ability to take oral medications * Competent to sign and date an Institutional Review Board approved informed consent form * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Platelet count ≥ 100 x 109/L * Hemoglobin \> 9 g/dL * Prothrombin time (PT) or partial thromboplastin time (PTT) \< 1.5 x upper limit of normal (ULN) * Serum creatinine \< 2.0 mg/dL * Calculated creatinine clearance ≥ 50 ml/min * AST \< 2.5 x ULN (if liver or bone metastases are present, ≤ 5 x ULN) * ALT \< 2.5 x ULN (if liver or bone metastases are present, ≤ 5 x ULN) * Alkaline phosphatase \< 2.0 x ULN (if liver or bone metastases are present, ≤ 5 x ULN) * Total bilirubin \< 1.5 x ULN
Exclusion criteria
* Active parenchymal brain metastases. Subjects who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 are eligible if they meet all of the following criteria: a) residual neurological symptoms grade \< 1; b) no dexamethasone requirement; and c) follow-up MRI shows no new lesions appearing * Prior bone marrow transplant (autologous or allogeneic) * History or presence of hematological malignancies * History of bleeding diathesis * Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association \> class II), unstable angina, or unstable cardiac arrhythmia requiring medication * Active peptic ulcer disease * Gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (eg, Crohn's disease, ulcerative colitis) * Active infection requiring intravenous (IV) antibiotics within 2 weeks of study enrollment (day 1) * Known positive test for HIV * Active or chronic hepatitis B or hepatitis C infection, determined by serologic tests * Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia * Anti-tumor therapy within 28 days of study day 1; concurrent use of hormone deprivation therapy for hormone-refractory prostate cancer or breast cancer is permitted * Treatment with immune modulators including, but not limited to, corticosteroids, cyclosporine and tacrolimus within two weeks prior to enrollment * Therapeutic or palliative radiation therapy within two weeks of study day 1 * Systemic anticoagulation therapy, including warfarin, within 28 days of day 1 * Prior treatment with aurora inhibitors * Prior participation in an investigational study (drug or device) within 28 days of study day 1 * Major surgery within 28 days of study day 1 * Any co-morbid medical disorder that may increase the risk of toxicity, in the opinion of the investigator or sponsor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety: subject incidence of adverse events, first-cycle DLTs and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests | 1 year |
| PK profile: AMG 900 PK parameters including, but not limited to, maximum observed concentration (Cmax), minimum observed concentration, area under the plasma concentration-time curve and, if feasible, half-life | 1 year |
| Change in levels of p-Histone H3 from baseline (part 1 - dose escalation only) | 1 year |
| Response rate in each taxane-resistant tumor type assessed per RECIST guidelines (part 2 - dose expansion only) | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Tumor response measured by CT or MRI and assessed per RECIST guidelines | 1 year |
| Change from baseline in maximum standardized uptake value (SUVmax) using 18FLT-PET/CT (part 2 - dose expansion only) | 1 year |
| Change in tumor volume from baseline measured by volumetric CT or MRI | 1 year |
Countries
Australia, United States
Outcome results
None listed